Zevra Therapeutics, Inc. ZVRA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s accrued expenses?
- Zevra Therapeutics, Inc. (ZVRA) reported accrued expenses of $1.41M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Zevra Therapeutics, Inc.'s accrued expenses decreased by 58.6% year-over-year, from $3.4M to $1.41M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s accrued expenses has grown at a 51.3% compound annual growth rate (CAGR), from $172K to $1.36M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.